-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, URX6ddAZoLOTIkIx8B1hmAxf/57Rf+QBWEshhmBWE/kWO4pPR14/Z/npo6P6AGWE dA4MeATumISS0Pnk+fyGcw== 0001104659-05-032847.txt : 20060606 0001104659-05-032847.hdr.sgml : 20060606 20050719072822 ACCESSION NUMBER: 0001104659-05-032847 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 CORRESP 1 filename1.htm

 

Interleukin Genetics, Inc.

135 Beaver Street, Waltham MA 02254

 

 

July 18, 2005

 

 

VIA EDGAR SUBMISSION

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Todd Sherman

 

Re:

Interleukin Genetics, Inc.

 

Form 10-K for Fiscal Year Ended December 31, 2004

 

File No: 000-23413

 

Ladies and Gentlemen:

 

In response to the letter dated July 7, 2005 from Jim B. Rosenberg of the Staff, Interleukin Genetics, Inc. (the “Company”) hereby acknowledges the following:

 

•                  The Company is responsible for the adequacy and accuracy of the disclosure in its filings;

 

•                  Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filings; and

 

•                  The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

 

Very truly yours,

 

 

 

Interleukin Genetics, Inc.

 

 

 

By:

/s/ Fenel M. Eloi

 

 

Fenel M. Eloi

 

Chief Financial Officer,

 

Chief Operating Officer and Secretary.

 

 -----END PRIVACY-ENHANCED MESSAGE-----